Psilocybe Cyanofibrillosa
"Blue Fibrillose Psilocybe"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanofibrillosa-1_new-800x450.webp)
Scientific Classification
About
Psilocybe cyanofibrillosa, known as the Blue Fibrillose Psilocybe, is a moderately potent psilocybin mushroom native to the Pacific Northwest of North America. It is recognized for its distinctive bluish fibrils (fibrous threads) on the cap and stem, especially when bruised. Though less well-known than its relatives like P. cyanescens, it shares similar psychoactive properties and grows in similar habitats.
History
This species was first described in the late 20th century and has been found primarily in coastal regions of Washington, Oregon, and British Columbia. It often grows in wood chips, forest debris, and along streambanks—especially in areas rich in lignin or decaying wood.
Although not widely cultivated, it has become of interest to mycologists and psychonauts due to its subtle but distinctly uplifting and visual effects. Its name reflects the characteristic blue fibrils on the cap and stem—an identifying feature among psilocybin-containing species.
Overview
The mushroom has a convex to flat cap, measuring 1.5–4 cm across, with a reddish-brown to caramel color that darkens when wet. It is covered in fine bluish fibrils, especially near the margin and on the stem, which bruises blue when touched. The gills are adnate and turn dark purple-brown as spores mature.
The effects are described as gentle, clear-headed, and euphoric, with moderate visual and emotional depth. It is usually consumed fresh or dried and is appreciated for its calming and nature-connected experiences. Potency is considered moderate, making it suitable for those seeking a less intense psychedelic experience.
Physical Characteristics
Caps:
Convex to broadly convex, sometimes with a low umbo, 1-3 cm wide, yellowish-brown to reddish-brown, with blue fibrils on the surface
Gills:
Adnate to adnexed, initially pale, becoming purplish-black with age
Psychoactive Effects
Euphoric
Describing intense feelings of happiness or excitement
Perceptual
The change in the way things are perceived, including changes in time perception, spatial perception, and perception of one's own body.
Pharmacology
Helps With
Depression
Relieves symptoms of depression, improving mood and outlook
Anxiety
Helps to alleviate feelings of worry, fear, and unease
Addiction
Helps to overcome addiction and substance abuse
PTSD
Helps to alleviate symptoms of post-traumatic stress disorder
OCD
Helps to alleviate symptoms of obsessive-compulsive disorder
ADD ADHD
Helps to alleviate symptoms of attention deficit disorder and attention deficit hyperactivity disorder
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines. A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
A feeling of discomfort in the stomach with an urge to vomit
Chemical Constituents
Medicinal Chemistry
Similar Species
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanescens-1_new-400x400.webp)
Species: Psilocybe cyanescens
Edibility: Psychoactive
Key Differences: P. cyanescens lacks the distinct blue fibrils on the cap and stem, and its cap has a more wavy margin compared to P. cyanofibrillosa.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanescens-1_new-400x400.webp)
Species: Psilocybe cyanescens
Edibility: Psychoactive
Mushroom Ratings
0.0
Based on 0 Reviews
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
References
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .
- Schindler, E. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. .
- Raval, N. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. .
- Kuypers, K. (2019). Psychedelic medicine: The biology underlying the persisting psychedelic effects. .